Drug Target Review

JULY 28, 2025

When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?

52

52

BioPharma Drive: Drug Pricing

JULY 28, 2025

Skip to main content Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

130

130

Covalent Modifiers

JULY 24, 2025

Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.

Research 130

Research 130

Broad Institute

JULY 21, 2025

Prime editing treats childhood brain disease in mice By Corie Lok July 21, 2025 Breadcrumb Home Prime editing treats childhood brain disease in mice Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.

Disease 141

Disease Laboratories Treatment DNA 141

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Drug Target Review

JULY 21, 2025

Hundreds of life-altering conditions attack the central nervous system (CNS). Disorders such as Alzheimer’s disease , primary glioblastoma and amyotrophic lateral sclerosis (ALS) all affect the CNS and are considered fatal, while more common conditions, including depression , strokes and epilepsy , require long-term treatments. According to the World Health Organization (WHO) , neurological conditions are now the number one cause of ill health and disability across the globe, 1 highlighting the

Drug Development 65

Drug Development Small Molecule Drugs Therapies 65

Science Daily: Pharmacology News

JULY 25, 2025

Millipedes, often dismissed as creepy crawlies, may hold the secret to future painkillers and neurological drugs. Researchers at Virginia Tech discovered unique alkaloid compounds in the defensive secretions of a native millipede species. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.

Therapies 172

Therapies Drug Research Drugs Research 172

The Open Targets Blog

JULY 23, 2025

How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.

Bioinformatics 52

Bioinformatics Research Disease International 52

Broad Institute

JULY 24, 2025

Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets By Leah Eisenstadt July 24, 2025 Breadcrumb Home Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.

Virus 81

Virus RNA Laboratories Drugs 81

Drug Target Review

JULY 24, 2025

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further

Immune Response 52

Immune Response Engineering Cell Based Assays Therapies 52

Science Daily: Pharmacology News

JULY 25, 2025

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinica

Virus 269

Virus Immune Response Clinical Trials Trials 269

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Covalent Modifiers

JULY 23, 2025

Fernando, M. C., Craven, G. B., & Shokat, K. M. Small GTPases, 2024 15(1), 1–7. [link] KRAS is the most frequently mutated oncogene in human cancer. In multiple types of cancer, a missense mutation at codon 12 substitutes a glycine for a cysteine, causing hyperactivation of the GTPase and enhanced MAPK signalling. Recent drug discovery efforts culminating from work during the past decade have resulted in two FDA-approved inhibitors, sotorasib and adagrasib, which target the KRASG12C mutant a

FDA Approval 130

FDA Approval Clinical Trials FDA Trials 130

Drugs.com

JULY 21, 2025

MONDAY, July 21, 2025 -- The U.S. Food and Drug Administration has approved a prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster). The existing vaccine consists of two.

Vaccine 199

Vaccine FDA Approval FDA Drugs 199

Crown Bioscience

JULY 21, 2025

In the complex landscape of oncology research and drug development, reliable preclinical models are crucial. Among various available platforms, cell line-derived xenografts (CDX) stand out as a robust and highly valuable model system, offering unique advantages for understanding tumor biology, drug efficacy, and therapeutic potential. This article explores the pivotal role of CDX models in preclinical cancer research, emphasizing their utility in drug discovery and development processes.

Drugs 52

Drugs Drug Development Research 52

Drug Target Review

JULY 21, 2025

In Part 2 of our conversation with Layla Hosseini-Gerami, Chief Data Science Officer at Ignota Labs , we explore the many forms of toxicity and how AI-powered tools like omics and cell painting are transforming early prediction in pre-clinical research. The conversation revealed important distinctions between different types of toxicity and our current ability to predict them: “For certain types of toxicity like liver and cardio, I think those are quite well understood in terms of the mech

Drugs 73

Drugs RNA Bioinformatics Science 73

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Chemical Biology and Drug Design

JULY 23, 2025

Liver cancer is a form of aggressive tumor, with HCC accounting for most of its occurrences. Traditional Chinese herbal medicines are well-known for their low risks of adverse events and anticancer effects. HMA, the main active ingredient of Hedyotis diffusa Willd , has been shown to suppress the growth of several malignancies. Therefore, this study examined the effects of HMA in HCC.

Protein Expression 100

Protein Expression Treatment Research 100

Covalent Modifiers

JULY 25, 2025

Xue Li, Ru Li, Xiaoxia Zhu et al. Research Square Preprint, 23 July 2025, [link] Orelabrutinib is a highly selective, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). It has shown promising results in animal models, indicating potential for treating systemic lupus erythematosus (SLE). A multicentre, double-blind, randomised, placebo-controlled, phase Ib/IIa trial (NCT04305197) was conducted.

Treatment 100

Treatment Trials Research 100

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it described as "subpotent" active ingredients. The recall of more than 160,000 bottles of.

FDA 304

FDA Drugs 304

Sygnature Discovery

JULY 24, 2025

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority.

Laboratories 52

Laboratories Disease Science Drugs 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Science Daily: Pharmacology News

JULY 23, 2025

Scientists have discovered a sugar compound from deep-sea bacteria that can destroy cancer cells in a dramatic way. This natural substance, produced by microbes living in the ocean, causes cancer cells to undergo a fiery form of cell death, essentially making them self-destruct. In lab tests and in mice with liver cancer, the compound not only stopped tumors from growing, but also activated the immune system to fight back.

Treatment 279

Treatment 279

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — Insulin delivered by nasal spray might be a potential treatment for Alzheimer’s disease, a new study says. An insulin nasal spray effectively reached key memory regions in the brains of a small group of older.

Treatment 232

Treatment Disease 232

New Drug Approvals

JULY 25, 2025

Vamorolone CAS 13209-41-1 Molecular Weight 356.46 Formula C 22 H 28 O 4 Agamree 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione VBP-15 free alcohol (8 S ,10 S ,13 S ,14 S ,16 R ,17 R )-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6 H -cyclopenta[a]phenanthren-3-one (16alpha)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

Predictive Oncology

JULY 21, 2025

Drug repurposing using the Predictive Oncology machine learning approach and proprietary biobank of frozen dissociated tumor cells (DTCs) is outlined in this new white paper. An expedient workflow for identifying drugs that are good candidates for repurposing is demonstrated in this brand-new white paper. The Predictive Oncology machine learning approach paired with our proprietary biobank of frozen dissociated tumor cells (DTCs) offers a screening opportunity for many repurposing candidates to

Drugs 52

Drugs 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Science Daily: Pharmacology News

JULY 25, 2025

Fermenting stevia with a banana leaf-derived probiotic turns it into a powerful cancer-fighting agent that kills pancreatic cancer cells while sparing healthy ones. The secret lies in a metabolite called CAME, produced through microbial transformation.

176

176

Collaborative Drug

JULY 24, 2025

CDD Vault Update (July #2 2025) Search Inventory by Molecule & Batch Fields, Protocol Plate Locations, Stoichiometry Table Debiting, Synonym Links in ELN, Chemical Properties in Structure Editor

166

166

Drug Patent Watch

JULY 24, 2025

"Patent Strategy 2.0: Why Your Law Firm's Playbook May Be Holding You Back As the pharmaceutical industry continues to evolve at breakneck speed, one thing remains constant: the importance of a robust patent strategy. But are your lawyers playing by the same old rules? A new framework is emerging that's shaking up the status quo and giving companies a competitive edge.

Pharmaceutical Companies 56

Pharmaceutical Companies Pharmaceuticals 56

ACTO

JULY 23, 2025

A Specialized Practice Environment to Sharpen Clinical Fluency, Master Product Messaging, and Drive Continuous Improvement Through a Gamified Experience BTORONTO and NEW YORK– July 24, 2025 — ACTO , a leader in AI-first commercial learning, enablement, and customer engagement solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today announced the launch of CxZone , the first and only AI-simulated roleplay solution exclusively designed for pharmaceu

Science 52

Science Production FDA Compliance 52

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic hand eczema (CHE). CHE is common condition marked by redness, itching and cracking on the.

FDA Approval 230

FDA Approval FDA Drugs 230

Science Daily: Pharmacology News

JULY 26, 2025

A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.

Drugs 133

Drugs 133

Chemical Biology and Drug Design

JULY 23, 2025

Spalt-like transcription factor 4 (SALL4) mediates fatty acid oxidation (FAO) promotes 5-fluorouracil (5-FU) resistance in gastric cancer (GC) cells. ABSTRACT Platinum-based and pyrimidine drugs are first-line treatments for gastric cancer (GC), but their efficacy is often affected by drug resistance. High spalt-like transcription factor 4 (SALL4) expression is associated with poor prognosis, but its role in 5-fluorouracil (5-FU) resistance is not yet clear.

Bioinformatics 100

Bioinformatics Drug Development Treatment Research 100

Drug Patent Watch

JULY 23, 2025

"Breaking the Patent Barrier: The Unseen Hurdles in Generic Drug Development As the pharmaceutical industry grapples with rising costs and accessibility concerns, generic drug development has emerged as a beacon of hope. However, behind the scenes, generic manufacturers are facing a daunting challenge: overcoming formulation hurdles that can make or break the success of a generic drug.

Drug Development 84

Drug Development Drugs Pharmaceuticals 84

Collaborative Drug

JULY 22, 2025

Drug Discovery Industry Roundup with Barry Bunin — July 22, 2025

Drugs 189

Drugs 189

Alta Sciences

JULY 23, 2025

Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte pmjackson Wed, 07/23/2025 - 17:38 CYTO 2025 , the 38th annual Congress of the International Society for the Advancement of Cytometry, is the premier, inclusive, and international conference on the many facets of cytometry science and engineering.

International 52

International Science Drug Development Laboratories 52

Science Daily: Pharmacology News

JUNE 26, 2025

Imagine detecting a single trillionth of a gram of a molecule—like an amino acid—using just electricity and a chip smaller than your fingernail. That’s the power of a new quantum-enabled biosensor developed at EPFL. Ditching bulky lasers, it taps into the strange world of quantum tunneling, where electrons sneak through barriers and release light in the process.

Disease 159

Disease 159